Sellers (Exploring): Blackstone / TPG
Asset: Hologic surgical unit — gynecological surgical equipment
Sector: Medical technology, women's health, minimally invasive gynecological surgery
Reported Target Valuation: Above $4 billion
Status: Exploratory — advisors engaged; no binding agreement in place
Source: Reuters, citing Financial Times reporting

Blackstone and TPG completed the take-private of Hologic, Inc. in April 2026. According to Hologic's own disclosure, the transaction closed on April 7, 2026. Hologic is a medical technology company focused on women's health, with business lines spanning diagnostics, breast health imaging, skeletal health, and surgical products.

The take-private converted Hologic from a publicly listed company to a privately held portfolio company of Blackstone and TPG. Transactions of this scale typically involve significant leverage — debt financing secured against the acquired company's assets and cash flows — which creates pressure to generate liquidity through asset monetization in the near term.

Hologic's surgical segment produces equipment used in minimally invasive gynecological procedures. The product portfolio includes devices used in endometrial ablation, hysteroscopy, and related interventional procedures. This segment serves hospital systems, ambulatory surgical centers, and gynecological practices, with revenue derived from both capital equipment sales and recurring consumable and service revenue.

The surgical unit is a strategically coherent carve-out candidate for several reasons:

• It is operationally distinct from Hologic's diagnostics and imaging businesses
• It has an identifiable customer base (gynecological surgeons and hospital procurement) that differs from the diagnostic laboratory and radiology buyers for other Hologic segments
• The recurring consumable revenue component makes it attractive to both strategic acquirers and healthcare-focused private equity buyers
• At a reported target above $4 billion, it represents a meaningful liquidity event relative to the overall take-private transaction size

The reported exploration of a Hologic surgical unit sale — within approximately three months of the take-private closing — reflects a pattern that has become increasingly common in large-scale PE transactions:

Rapid post-closing carve-out to reduce leverage
Large take-private transactions are typically financed with significant debt. Selling a non-core or separately valued business unit shortly after closing allows the PE sponsors to reduce the debt burden on the remaining portfolio company, improving credit metrics and reducing interest expense.

Value arbitrage between conglomerate and standalone multiples
A focused medical device company with a clear women's health surgical identity may command a higher valuation multiple as a standalone entity than as a segment within a diversified diagnostics and imaging conglomerate. PE sponsors routinely assess whether sum-of-parts value exceeds the whole.

Accelerating investor return timelines
Distributing proceeds from a carve-out sale to fund investors earlier in the hold period improves IRR metrics, even if the total absolute return is similar to a later exit. This is particularly relevant in the current environment where PE fund vintages are under pressure to demonstrate liquidity.

No formal regulatory process has been initiated, as no binding agreement has been announced. If the transaction proceeds, several regulatory and diligence workstreams would be relevant:

HSR / Antitrust
A sale above $4 billion to a strategic acquirer in the medical device space would likely require Hart-Scott-Rodino pre-merger notification. The relevant market definition — minimally invasive gynecological surgical equipment — would need to be analyzed for concentration effects if the buyer has overlapping products.

FDA and Medical Device Regulation

• The surgical unit's products are FDA-regulated medical devices; any change of ownership requires analysis of existing 510(k) clearances, PMA approvals, and quality system registrations
• The buyer would need to assume or re-register device authorizations; the transition mechanics for FDA-regulated products require careful planning
• Post-market surveillance obligations and adverse event reporting systems would need to be transferred

Quality System and Product Liability Due Diligence

• ISO 13485 quality management system documentation and audit history
• Product liability claims history and insurance coverage
• Recall history and any open FDA enforcement actions or warning letters

Patent and Know-How Transfer

• Identification of patents, trade secrets, and clinical data attributable to the surgical unit
• Separation of shared IP used across multiple Hologic business segments
• Freedom-to-operate analysis for key surgical platform technologies

Hospital and Distributor Contracts

• Review of GPO (group purchasing organization) agreements and hospital system contracts for change of control provisions
• Distributor agreements in international markets — many will contain assignment restrictions or termination rights triggered by a change of ownership

Transition Service Agreements

• Shared manufacturing, regulatory affairs, quality, and back-office functions that the surgical unit relies on from Hologic's broader infrastructure will require TSA coverage during the separation period

For practitioners advising on healthcare carve-outs from PE-owned platforms, this process highlights several key workstreams:

Seller-Side Preparation

• Carve-out financial statements — audited standalone financials for the surgical unit, separating shared costs and intercompany transactions
• Regulatory asset mapping — complete inventory of FDA clearances, approvals, and registrations attributable to the unit
• IP separation analysis — identifying which patents and trade secrets are unit-specific versus shared across Hologic

Buyer-Side Diligence

• Clinical and commercial pipeline assessment — what products are in development and what is the regulatory pathway to market
• Reimbursement landscape — CPT codes, coverage policies, and reimbursement trends for the relevant gynecological procedures
• Competitive positioning — market share in endometrial ablation and hysteroscopy relative to competitors

Financing Considerations

• At above $4 billion, a strategic acquirer would likely require significant debt financing; lenders will conduct their own diligence on FDA regulatory status and product liability exposure
• A PE buyer would structure the acquisition with leverage against the surgical unit's recurring consumable revenue stream

The Hologic surgical unit process is relevant to Turkish medical technology companies, healthcare investors, and distributors in several respects:

• Post-take-private carve-out pattern — Turkish PE funds and family office investors evaluating U.S. healthcare assets should anticipate that large take-private transactions will generate carve-out opportunities in the 12-36 months following closing; monitoring PE portfolio company structures is a valuable deal sourcing strategy
• FDA regulatory transfer mechanics — Turkish medical device companies acquiring U.S. FDA-cleared products need to understand the device authorization transfer process; this is a material transaction risk that affects closing timelines and post-closing operations
• Distributor agreement change of control — Turkish distributors of Hologic products in Turkey and the broader region should review their distribution agreements for change of control provisions that may be triggered by a sale of the surgical unit
• Women's health as a strategic sector — Turkish healthcare investors and hospital groups with women's health focus should monitor this process as a potential acquisition or distribution partnership opportunity

This post is part of ULF New York’s M&A monitoring series, tracking significant transactions across U.S. and Turkish-American cross-border practice areas. It does not constitute legal advice.